Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvotech Chases Debt Backup As Shareholders Redeem From The Pot

Newly Public Company Has $128m In Available Cash

Executive Summary

Alvotech is furthering efforts to have a debt facility in place worth up to $125m as it kicks off life as a public company, amid challenging global market conditions.

You may also be interested in...



Alvotech Acquires Reykjavik Manufacturing Facility Amid $136m Financing Boost

Months after it become a public company, Alvotech has once again turned to the debt/equity markets to provide financial firepower for its pipeline of biosimilar candidates.

Stada And Alvotech Launch Higher-Strength Adalimumab In Europe

Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.

Alvotech’s Ustekinumab Passes Safety And Efficacy Milestone

Alvotech has announced success in its confirmatory clinical safety and efficacy study for its AVT04 ustekinumab candidate, a proposed biosimilar to Stelara.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel